Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?

QR Code

Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Fiammetta Cosci, Giovanni A. Fava
Format:	article
Langue:	EN
Publié:	Karger Publishers 2021
Sujets:	Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/5832f5c3fe76477db14a7591c4d0f900
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Major depressive disorder: mechanism-based prescribing for personalized medicine
par: Saltiel PF, et autres
Publié: (2015)

Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
par: F Kheirkhah, et autres
Publié: (2010)

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.
par: Jan Wolff, et autres
Publié: (2021)

Pharmacotherapy of panic disorder
par: Charles B Pull, et autres
Publié: (2008)

Deciding not to decide: computational and neural evidence for hidden behavior in sequential choice.
par: Sebastian Gluth, et autres
Publié: (2013)

Demographic and clinical features and prescribing patterns of psychotropic medications in patients with the melancholic subtype of major depressive disorder in China.
par: Yu-Tao Xiang, et autres
Publié: (2012)

How to decide whether to move species threatened by climate change.
par: Tracy M Rout, et autres
Publié: (2013)

Identification of Gene Co-Expression Modules and Core Genes Related to Immune Disorders in Major Depression Disorder
par: Zhang L, et autres
Publié: (2021)

Investigating How Technology Innovation is Decided and Implemented in a Interorganizational Collaboration
par: Genevieve Gallant
Publié: (2005)

Symptoms of major depressive disorder during the COVID-19 pandemic: results from a representative sample of the Canadian population
par: Margot Shields, et autres
Publié: (2021)

Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent?
par: Maurizio Pompili, et autres
Publié: (2008)

EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
par: Muhammad Siddique Kakar, et autres
Publié: (2020)

Cognitive Behavioral Therapy and Pharmacotherapy for the Treatment of Tobacco Use Disorder in Primary Care for Resident Physicians
par: Juhee C. McDougal, et autres
Publié: (2019)

Veronika decide morir
par: Coelho, Paulo
Publié: (1999)

Prescribing pattern of benzodiazepines in outpatients without a diagnosis of mental disorders: Retrospective study
par: Stanetić Kosana D., et autres
Publié: (2021)

How the brain decides when to work and when to rest: dissociation of implicit-reactive from explicit-predictive computational processes.
par: Florent Meyniel, et autres
Publié: (2014)

Desvenlafaxine in the treatment of major depressive disorder
par: Maria Teresa C Lourenco1, et autres
Publié: (2009)

Baseline symptom profile does not predict early response to electroconvulsive therapy (ECT) in major depressive disorder (MDD)
par: Bijan Zarrabi, et autres
Publié: (2021)

Patient and Clinician Satisfaction With Diabetes Group Visits in Community Health Centers
par: Samantha E Mannion MD, et autres
Publié: (2021)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
par: Findeisen KE, et autres
Publié: (2021)

Psychiatric comorbidities in patients with major depressive disorder
par: Thaipisuttikul P, et autres
Publié: (2014)

Predictors of Major Depressive Disorder in Older People
par: Susana Sousa, et autres
Publié: (2021)

Disturbances of mitochondrial parameters to distinguish patients with depressive episode of bipolar disorder and major depressive disorder
par: Zvěřová M, et autres
Publié: (2019)

Level of agreement between self-rated and clinician-rated instruments when measuring major depressive disorder in the Thai elderly: a 1-year assessment as part of the THAISAD study
par: Wongpakaran N, et autres
Publié: (2014)

ATTITUDE OF CLINICIANS TOWARDS CLINICAL DECISION-MAKING IN PROSTHODONTICS
par: Danish Azeem Khan, et autres
Publié: (2021)

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
par: Weiller E, et autres
Publié: (2017)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
par: Chimenti MS, et autres
Publié: (2020)

The pharmacotherapy of acute viral hepatitis B: a clinical pharmacist's view
par: O.Yu. Horodnycha, et autres
Publié: (2020)

Vosotros, cuando oréis, decid Padre nuestro /
par: Vílchez, José
Publié: (2005)

MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective
par: Miguel A. Ortega, et autres
Publié: (2021)

Plasma proteomic data in bipolar II disorders and major depressive disorders
par: Hyunju Lee, et autres
Publié: (2021)

Biologic Treatments of Psoriasis: An Update for the Clinician
par: Brownstone ND, et autres
Publié: (2021)

Exploring Primary Care Clinicians’ Views about How Best to Implement a Potential Trial around Point-of-Care Tests for Common Infections in South Africa
par: Alice Epps, et autres
Publié: (2021)

Why, When and How Should Clinicians Use Physiology in Patients with Acute Coronary Syndromes?
par: Roberto Scarsini, et autres
Publié: (2020)

Pharmacotherapy Update and Review for Family Medicine Residents Using Jeopardy-Style Game
par: Giselle Ellis
Publié: (2020)

The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
par: Jeon SW, et autres
Publié: (2018)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
par: Mazen K Ali, et autres
Publié: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
par: J Craig Nelson, et autres
Publié: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
par: Tobe EH
Publié: (2013)

Levomilnacipran for the treatment of major depressive disorder: a review
par: Asnis GA, et autres
Publié: (2015)